IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved

Rhea-AI Summary

IceCure (Nasdaq: ICCM) announced on Feb. 9, 2026 that Chief Financial Officer Ronen Tsimerman will depart after nearly nine years to pursue new opportunities but will remain in his role until a successor is appointed to ensure a smooth transition.

The company has launched a CFO search and reports several compelling candidates advancing to board interviews. Management credited Tsimerman with helping achieve key milestones, including the Nasdaq listing, fundraisings to complete the ICE3 study, and U.S. FDA marketing clearance of ProSense® for low-risk breast cancer in late 2025.

Positive

• CFO will remain until successor appointed, ensuring transitional continuity
• Company reports candidates advancing to board interviews for CFO role
• CFO credited with enabling Nasdaq listing and fundraisings for ICE3 study
• U.S. FDA marketing clearance of ProSense for low-risk breast cancer (late 2025)

Negative

• Loss of long-tenured CFO after nearly nine years may create short-term leadership gap
• Ongoing CFO search introduces near-term execution and investor-sentiment uncertainty

News Market Reaction – ICCM

+1.84%

1 alert

+1.84% News Effect

On the day this news was published, ICCM gained 1.84%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

CFO tenure: nine years

1 metrics

CFO tenure nine years Length of service of outgoing CFO Ronen Tsimerman at IceCure

Market Reality Check

Price: $0.6300 Vol: Volume 288,612 is 14% abo...

normal vol

$0.6300 Last Close

Volume Volume 288,612 is 14% above the 20-day average of 252,092 (relative volume 1.14). normal

Technical Price $0.5911 is trading below the 200-day MA at $0.88 and 64.39% below the 52-week high, but 9.44% above the 52-week low.

Peers on Argus

ICCM was up 7.04% pre-news with mixed peers: LUNG, VNRX, and APYX up between 2.4...

ICCM was up 7.04% pre-news with mixed peers: LUNG, VNRX, and APYX up between 2.43–4.62%, while BDMD and TELA were down 1.55% and 0.72%, suggesting a company-specific move rather than a uniform sector rotation.

Historical Context

5 past events · Latest: Jan 28 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 28	Guideline draft news	Positive	+0.0%	ASBrS draft guide proposes cryoablation for select low-risk breast cancer patients.
Jan 15	Dividend tax detail	Neutral	-0.5%	AIV discloses 2025 dividend tax allocation and references plan of sale and liquidation.
Jan 12	Sales and FDA update	Positive	-5.5%	Preliminary record 2025 ProSense® sales and FDA marketing authorization for low-risk breast cancer.
Dec 17	Sales outlook news	Positive	+8.7%	Expectation of record Q4 North American sales following FDA authorization-driven demand.
Dec 10	Clinical data update	Positive	+3.1%	Four independent RSNA studies report strong ProSense® cryoablation outcomes across 263 patients.

Pattern Detected

Recent fundamentally positive ICCM news often saw muted or even negative next-day moves, with only 2 of 4 positive company updates aligning with price strength.

Recent Company History

Over the past few months, ICCM highlighted several milestones: record ProSense® sales of about $3.4M in 2025, FDA marketing authorization in October 2025 for low-risk breast cancer, and strong clinical data from four independent RSNA 2025 studies. An ASBrS draft guideline in Jan 2026 proposed including cryoablation for select low-risk patients. Price reactions were mixed: some positive clinical and commercial updates on Dec 17, 2025 and Dec 10, 2025 aligned with gains, while others in Jan 2026 saw flat or negative responses.

Market Pulse Summary

This announcement details a planned CFO departure after nine years, with the incumbent remaining unt...

Analysis

This announcement details a planned CFO departure after nine years, with the incumbent remaining until a successor is appointed, emphasizing continuity. It references key achievements, including Nasdaq listing, fundraisings, the ICE3 study, and late‑2025 FDA marketing clearance of ProSense® for low‑risk breast cancer. In light of recent record ProSense® sales and growing clinical validation, observers may focus on how the next CFO supports commercialization, financing plans, and regulatory engagement.

Key Terms

cryoablation, u.s. food and drug administration, marketing clearance, on-label treatment

4 terms

cryoablation medical

"a developer of minimally-invasive cryoablation technology that destroys tumors by freezing"

A medical treatment that uses extreme cold to freeze and destroy unwanted tissue, such as small tumors or heart tissue causing irregular rhythms; think of it like applying a focused freezer to stop a problem spot without cutting it out. It matters to investors because devices, tools, and drugs tied to cryoablation, plus clinical results, approval status and insurance coverage, can drive sales, shape market adoption and affect the financial outlook of healthcare companies.

u.s. food and drug administration regulatory

"the subsequent U.S. Food and Drug Administration marketing clearance of ProSense"

The U.S. Food and Drug Administration is the federal agency that evaluates and enforces safety, effectiveness and labeling standards for medicines, medical devices, vaccines, food and related products before they reach consumers. For investors it matters because FDA approvals, warnings or recalls determine whether a product can be sold, how quickly it reaches the market and how costly compliance will be—changes that directly affect a company’s revenue, costs and stock value.

marketing clearance regulatory

"and the subsequent U.S. Food and Drug Administration marketing clearance of ProSense"

Marketing clearance is official permission from a government regulator to sell a medical product or device after regulators review safety, performance data, and the product’s instructions and packaging. For investors it is a key commercial milestone because it allows sales to begin, reduces regulatory uncertainty, and can unlock revenue and partnerships—much like a business license that lets a store legally open and operate.

on-label treatment regulatory

"bring the first and only on-label treatment in the U.S. for the minimally invasive treatment"

An on-label treatment is a drug or medical device used exactly as approved by regulators, matching the specific disease, patient group, dose and method listed on its official prescribing information. Investors care because on-label use usually means clearer insurance reimbursement, predictable sales and lower legal risk—think of it like selling a product exactly as the instruction manual describes versus using it in an unapproved way that can limit who will buy or pay for it.

AI-generated analysis. Not financial advice.

Ronen Tsimerman will continue as CFO until successor is appointed

CAESAREA, Israel, Feb. 9, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that after nearly a decade of service with IceCure, Chief Financial Officer Ronen Tsimerman has informed the Company of his decision to leave the Company to pursue new opportunities. The Company has initiated a search for a new Chief Financial Officer and has identified compelling candidates with significant experience commercializing disruptive technologies. Some candidates have recently advanced in the selection process to interviews with IceCure's Board of Directors. Mr. Tsimerman will continue in his role until a successor is appointed, to ensure a smooth transition.

"Ronen has been a valued contributor over the years, and his skilled financial and operational leadership allowed IceCure Medical to achieve several key milestones, including our listing on the Nasdaq, fundraisings to support the completion of our ICE3 study, the largest of its kind for cryoablation, and the subsequent U.S. Food and Drug Administration marketing clearance of ProSense® for low-risk breast cancer, in late 2025 ," stated IceCure's Chief Executive Officer, Eyal Shamir. "Ronen has been a trusted colleague and friend to our entire team and we wish him well in his future endeavors and are pleased to have his continued support over the next few months as we transition to a new CFO."

"I am extremely proud of the great work we've accomplished at IceCure. Our mission and the collaborative work with regulatory agencies, medical societies, caregivers and patients across the globe to bring the first and only on-label treatment in the U.S. for the minimally invasive treatment of low-risk breast cancer is truly an amazing accomplishment," Mr. Tsimerman stated. "I thank Eyal and the entire team for their professional excellence and partnership in advancing the Company's mission."

About ProSense®

The ProSense® Cryoablation System is the first and only medical device to receive FDA marketing authorization for the local treatment of low-risk breast cancer with adjuvant endocrine therapy for women aged 70 and above, including patients who are not suitable for surgical alternatives for breast cancer treatment. A full list of benefits and risks can be found on the Company's website.

ProSense® is a minimally invasive cryosurgical tool that provides the option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including in the breast, kidney, lung, and liver.

ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its easy, transportable design and liquid nitrogen utilization, ProSense® opens the door to fast and convenient office-based procedures for breast tumors.

About IceCure Medical

IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and Asia.

Forward Looking Statement

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses: the timing and completion of the planned transition of its Chief Financial Officer, the search for and appointment of a successor Chief Financial Officer, and the Company's expectations regarding continuity of financial leadership and operations during the transition period. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC on March 27, 2025, and other documents filed with or furnished to the SEC which are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

IR Contact:

Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914

Logo - https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/icecure-announces-planned-departure-of-cfo-following-nine-years-of-service-and-key-milestones-achieved-302682657.html

SOURCE IceCure Medical

FAQ

Why is IceCure (ICCM) CFO Ronen Tsimerman leaving and when is the departure effective?

He is leaving to pursue new opportunities and will stay until a successor is appointed. According to IceCure, Tsimerman informed the company of his decision after nearly nine years and will continue in his role to ensure a smooth transition.

How is IceCure (ICCM) handling the CFO transition and candidate progress?

IceCure has initiated a CFO search and reports candidates advancing to board interviews. According to IceCure, the company identified compelling candidates with experience commercializing disruptive technologies and several have progressed to interviews.

What milestones did IceCure (ICCM) credit the departing CFO with achieving?

Management cited the Nasdaq listing, fundraisings for the ICE3 study, and FDA clearance of ProSense in late 2025. According to IceCure, Tsimerman's financial leadership supported those specific corporate milestones.

Will the CFO departure affect IceCure's operations or regulatory activities?

The company intends continuity by keeping the CFO until a successor is named to limit disruption. According to IceCure, Tsimerman will remain in his role for the next few months to support the transition and ongoing operations.

What does the ProSense FDA clearance mean for IceCure (ICCM) after the CFO announcement?

ProSense FDA marketing clearance enhances the company's commercial position for low-risk breast cancer in the U.S. According to IceCure, the clearance occurred in late 2025 and is cited as a key milestone during the departing CFO's tenure.